U.S. Food and Drug Administration Commissioner Scott Gottlieb said a “rigged payment scheme” between several entities has resulted in restricted access to biosimilars.
Gottlieb made the comments Wednesday, referencing drug plans, insurers and pharmaceutical companies.
“Consolidated firms — the PBMs, the distributors, and the drug stores; team up with payers,” Gottlieb said at a conference. “They use their individual market power to effectively split monopoly rents with large manufacturers and other intermediaries; rather than passing on the saving garnered from competition to patients and employers.”
The FDA chief’s criticisms were heavy against titan pharmacy benefit managers, including Express Scripts Holding Co., CVS Health Corp. and UnitedHealth Group Inc.’s OptumRx unit.
To read more about Gottlieb’s sharp remarks, click here.